Igor Yu. Vinogradov

Igor Yu. Vinogradov

Auto-generated profile, based on publicly available information

Igor Yu. Vinogradov

Regional Clinical Oncology Dispensary

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2025 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
LZL.E. Zavalishina
L.E. Zavalishina
YAYu.YU. Andreeva
Yu.YU. Andreeva
ABA.A. Barinov
A.A. Barinov
IVI.YU. Vinogradov
I.YU. Vinogradov
SVSergey V Vtorushin
Sergey V Vtorushin
GFG.A. Frank
G.A. Frank
Immunohistochemical study is an integral component of modern morphologic diagnostics, providing accurate marker detection and identification of molecular subtypes of malignant neoplasms. A quality control system is fundamental in the aspect of standardizing laboratory protocols, ensuring reproducibility of results and increasing the reliability of diagnostic conclusions. Objective. To conduct a comprehensive assessment of the quality of immunohistochemical studies at the successive stages of the laboratory process (pre-analytical, analytical, post-analytical) in medical organizations that are participants of the external quality control program of the IHC Quality Control Center of Russian Medical Academy of Continuous Professional Education for 2024. Material and Methods. The present study analyzed the results of external quality control rounds initiated by the Quality Control Center. The nature and frequency of errors at all stages of immunohistochemical study, including procedures for fixation of biological material, methodology of immunohistochemical staining, and interpretation of the results obtained were evaluated. Analytical evaluation was carried out by experts in accordance with the criteria of international standards (CAP, NordiQC). Results. The analysis of the pre-analytical stage revealed methodological inconsistencies related to the processes of fixation of biological material, to the degree of DNA degradation and to the qualitative characteristics of histologic processing. At the analytical stage, the main errors were inadequate selection of antibodies and detection systems, and insufficient validation of diagnostic protocols. The postanalytic phase was characterized by a predominance of factors of incorrect conclusions, including errors in interpretation of HER2 status and molecular genetic subtypes of breast carcinoma. Repeated rounds of follow-up demonstrate that implementation of expert recommendations contributes to statistically significant improvements in diagnostic quality. Conclusion. The system of external quality control of immunohistochemical studies represents a key tool to optimize the accuracy and reproducibility of morphological diagnostics. Systematic participation of laboratories in control programs, standardization of methodological approaches and improvement of professional qualification of specialists ensure minimization of diagnostic errors and increase of clinical significance of research results.

8 October 2019 in I.P. Pavlov Russian Medical Biological Herald
Verified
Journal Article
Open access
PDF file
MBMariya Byakhova
Mariya Byakhova
AGAlexey Glazkov
Alexey Glazkov
IVIgor Yu. Vinogradov
Igor Yu. Vinogradov
GFGeorge A. Frank
George A. Frank
БМБяхова Мария Михайловна
Бяхова Мария Михайловна
Aim. To study the spectrum of cellular molecular-biological markers and identify those of them that can be used as prognostic factors for the clinical course of pulmonary adenocarcinoma. Material and Methods. In the given work archive material of 129 patients with confirmed diagnosis of pulmonary adenocarcinoma was used. In the work, histological, immunohistochemical, molecular-genetic and statistical methods were used. Results. In 29 cases (47.5%) of pulmonary adenocarcinoma, focal cytoplasmic and/or nuclear expression of p63 protein was observed in different proportions of cells. With expression of p63 in tumor cells, relapse-free survival was on average 25.7±5.1 months, while in patients with no expression of р63 it was 26.1±2.8 months. This parameter did not influence the overall survival of patients which was on average 33.6±2.7 months. Conclusion. A weak tendency to reduction of relapse-free survival of patients with p63-positive pulmonary carcinoma of lungs was revealed. Identification of p63 in pulmonary adenocarcinoma may be regarded as a factor of unfavorable prognosis and of risk of faster tumor progression, which requires further study to increase the statistical value of research.

16 April 2026 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
LZL.E. Zavalishina
L.E. Zavalishina
SVSergey V Vtorushin
Sergey V Vtorushin
GRG.A. Raskin
G.A. Raskin
SPS.V. Petrov
S.V. Petrov
YAYu.YU. Andreeva
Yu.YU. Andreeva
GFG.A. Frank
G.A. Frank
Immunohistochemistry is one of the key methods of modern morphological diagnostics, providing both differential diagnosis of neoplastic and non-neoplastic processes and the assessment of prognostic and predictive biomarkers relevant for the selection of drug therapy. The multistep nature of immunohistochemical studies is associated with a high risk of methodological errors at the preanalytical, analytical, and postanalytical stages, which may lead to reduced reproducibility of results and the development of clinically significant diagnostic inaccuracies. Objective. To assess the quality of immunohistochemical studies at all stages of the laboratory workflow in medical institutions participating in the external quality assessment program of the Immunohistochemistry Quality Control Center of the Russian Medical Academy of Continuous Professional Education in 2025. Material and methods. The results of 18 external quality assessment rounds covering the preanalytical, analytical, and postanalytical stages of immunohistochemical studies were analyzed. Expert evaluation was performed by the Expert Council of the Immunohistochemistry Quality Control Center in accordance with approved assessment criteria and current clinical guidelines. Results. At the preanalytical stage, typical violations related to fixation and histological processing of biological material were identified, significantly affecting the quality of immunohistochemical and molecular genetic studies. At the analytical stage, the main causes of unsatisfactory results were insufficient intralaboratory validation of protocols, the use of non-recommended antibody clones, and the absence of adequate control samples. At the postanalytical stage, errors in result interpretation not compliant with current clinical guideline requirements were detected. Laboratories that repeatedly participated in external quality assessment rounds demonstrated a statistically significant improvement in results following the implementation of individualized expert recommendations. Conclusion. External quality assessment of immunohistochemical studies is an effective tool for improving the reproducibility and clinical relevance of morphological research results. Regular participation of laboratories in quality control programs, standardization of methodological approaches, and systematic professional training of specialists contribute to a reduction in diagnostic errors and to improving the quality of morphological diagnostics and personalized patient management.